TIANFUCHEM N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide CAS NO.871700-17-3

product name: n-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phenyl]acetamide
synonyms: n-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phenyl]acetamide gsk-1120212;trametinib free base;mekinist trametinib;trametinib (gsk1120212,jtp 74057);trametinib, >=98%;acetamide, n-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phenyl]-;n-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-tri;gsk-1120212
cas: 871700-17-3
mf: c26h23fin5o4
mw: 615.3947932
einecs:
product categories: inhibitors;mapk;api;inhibitor;anti-cancer&immunity
mol file: 871700-17-3.mol
n-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phenyl]acetamide structure
n-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phenyl]acetamide chemical properties
density 1.74
safety information
safety statements 24/25
hs code 29339900

n-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phenyl]acetamide usage and synthesis
abstract trametinib (trade name mekinist) is a cancer drug. it is a mek inhibitor drug with anti-cancer activity.
trametinib(mekinist) is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (mek1) and mek2 activation and kinase activity. mek proteins are components of the extracellular signal-related kinase (erk) pathway. in melanoma and other cancers, this pathway is often activated by mutated forms of braf which activates mek. trametinib inhibits activation of mek by braf and inhibits mek kinase activity. trametinib inhibits growth of braf v600 mutant melanoma cell lines and demonstrates anti-tumor effects in braf v600 mutant melanoma animal models.
mekinist is indicated as monotherapy or in combination with tafinlar (dabrafenib) for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation.
biological activity trametinib (gsk1120212) is a highly specific and potent mek1/2 inhibitor with ic50 of 0.92 nm/1.8 nm in cell-free assays, no inhibition of the kinase activities of c-raf, b-raf, erk1/2.
in vitro for the different subtypes of raf and mek, with ic50 ranging from 0.92 nm to 3.4 nm，gsk1120212 inhibits the phosphorylation of mbp. gsk1120212 demonstrates no inhibition of the kinase activities of c-raf, b-raf, erk1 and erk2. in addition, gsk1120212 does not show drastic inhibitory activity against the other 98 kinases. gsk1120212 displays potent inhibitory activity against human colorectal cancer cell lines. ht-29 and colo205 cells, which are known to have a constitutively active b-raf mutant, are most sensitive to gsk1120212 with ic50 0.48 nm and 0.52 nm, respectively. the cell lines bearing a k-ras mutation show a wide range of sensitivity to gsk1120212 with ic50 of 2.2-174 nm. in contrast, colo320 dm cells, bearing the wild-type gene in both b-raf and k-ras, are found to be resistant to gsk1120212 even at 10 μm. gsk1120212 treatment for 24 hours induces cell-cycle arrest at the g1 phase in all sensitive cell lines. consistently, gsk1120212 treatment leads to upregulation of p15ink4b and/or p27kip1 in most of the colorectal cancer cell lines. gsk1120212 induces apoptosis both in ht-29 and colo205 cells, but that colo205 cells are more sensitive to gsk1120212 than ht-29 cells in terms of apoptosis induction.gsk1120212 blocks tumor necrosis factor-α and interleukin-6 production from peripheral blood mononuclear cells (pbmcs).
in vivo oral administration of gsk1120212 at 0.3 mg/kg or 1 mg/kg once daily for 14 days is effective in inhibiting the ht-29 xenograft growth, and 1 mg/kg of gsk1120212 can completely block the tumor increase. the phosphorylation of erk1/2 is completely inhibited in the established tumor tissues by single oral dose of 1 mg/kg gsk1120212, and both p15ink4b and p27kip1 protein levels are upregulated after 14 days of treatment with gsk1120212. in the colo205 xenograft model, tumor regression is observed even at a dose of 0.3 mg/kg. at a dose of 1 mg/kg, a complete regression is obtained in 4 out of 6 mice in which the tumor degenerates to the point that tumor volume is not measurable. administration of gsk1120212 at 0.1 mg/kg almost completely suppresses adjuvant-induced arthritis (aia) and type ii collagen-induced arthritis (cia) in lewis rats or dba1/j mice, respectively.